This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
ezh2
EZH2
EZH2 is the catalytic subunit of PRC2, trimethylating H3K27 → gene silencing; EZH2 Y641 gain-of-function mutation in ~25% of follicular lymphoma and ~10% of DLBCL silences tumor suppressors including CDKN2A; tazemetostat (EZH2 inhibitor) is FDA-approved for EZH2-mutant FL.
Entry Metadata
| Field | Value |
|---|---|
| ID | ezh2 |
| Name | EZH2 |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 03-molecular |
Cross-Atlas Connections
Sources
- Margueron R, Reinberg D. The Polycomb complex PRC2 and its mark in life. Nature. 2011;469(7330):343-349. · PubMed 21248841
- Morschhauser F, Tilly H, Chaidos A, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma (E7438-G-003): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2020;21(11):1433-1442. · PubMed 33035457